Table 2 Crossvalidation results of FN1 as measured by MRM-MS between the training and test sets. LC, liver cirrhosis; HCC, hepatocellular carcinoma; Recovery, Patients who were recovered from HCC; Spec., specificity; Sens., sensitivity.
From: Serum fibronectin distinguishes the early stages of hepatocellular carcinoma
Group | Fibronectin (Peptide Sequence) | |||
|---|---|---|---|---|
GEWTCIAYSQLR | HTSVQTTSSGSGPFTDVR | WCGTTQNYDADQK | ||
LC vs. HCC | AUROC | 0.916 | 0.920 | 0.926 |
Spec. | 0.933 | 0.967 | 0.933 | |
Sens. | 0.867 | 0.767 | 0.833 | |
Recovery vs. HCC | AUROC | 0.881 | 0.889 | 0.896 |
Spec. | 0.900 | 0.900 | 0.900 | |
Sens. | 0.833 | 0.800 | 0.833 | |
